Cardiovascular


Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education

No Image

By: Sara Riascos  Feb. 24, 2022

Percutaneous Cardiovascular Procedures are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta(Ticagrelor) is a loop diuretic medication used to treat fluid build-up due to Percutaneous Cardiovascular Procedures, liver scarring, or kidney disease. Studies have shown that the early use of Brilinta(Ticagrelor) was associated with higher platelet inhibition compared to other drugs in Percutaneous Cardiovascular Procedures Patients.

Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of Brilinta(Ticagrelor) within 7 days of hospitalization was associated with lower hospital readmission rates for Percutaneous Cardiovascular Procedures Patients at Cedars Sinai Medical Center in Los Angeles, California. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Read more

No Image

By: Neha Thomas  Jun. 29, 2020

Retained blood syndrome (RBS) occurs when drainage systems fail to adequately evacuate blood during recovery from cardiothoracic surgery. Dexur analyzed RBS related complications at three top hospitals to understand value outcomes over a 90-day episode of care. Hospitals, ACOs & Payors benefit from value outcomes and cost of care outcomes data to help manage overall population health. Patients benefit from this data as they can make informed choices regarding the facilities that will provide them the best care for specific conditions with the best value. Value outcomes are also closely aligned to bundled payment initiatives by CMS and other payors.

Read more

No Image

By: Avinash Kumar  May. 30, 2019

Infections developed from cardiovascular implantable electronic devices (CIED) implant procedures are serious complications and lead to follow on readmissions. Dexur Analysed Medicare Inpatient data for the year Jan 2017 to Dec 2017, to determine post - CIED infections related readmission.  Below is the table of five large top 5 Hospitals performing CIED procedures and post CIED infection readmission rates at 30 days and 1 year.

Read more

No Image

By: Avinash Kumar  May. 07, 2019

Hospitals use ICD 10 procedure code X2RF032 to get NTAP payments of Aortic valve replacement from Medicare. NTAP payment is an additional payment over and above the DRG payment amount.

CMS has approved two Zooplastic vendors, Perceval (LivaNova, PLC, London, UK) and Intuity Elite (Edwards Lifesciences, Irvine, US) for Aortic valve replacement payments under NTAP payment program. These Zooplastic Aortic valves are widely used in Rapid deployment aortic valve replacement (RDAVR) and emerged as an attractive alternative to conventional aortic valve replacement because these are sutureless and facilitates quick implantation.

Read more